JNJ-64281802
CR108919
Phase 2 small_molecule terminated
Quick answer
JNJ-64281802 for Dengue is a Phase 2 program (small_molecule) at Janssen Cilag International NV with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen Cilag International NV
- Indication
- Dengue
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated